A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Trial Profile

A Randomized, Double Blind Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

Completed
Phase of Trial: Phase II/III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Tecarfarin (Primary) ; Warfarin
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms EmbraceAC
  • Sponsors ARYx Therapeutics
  • Most Recent Events

    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 07 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH).
    • 08 Jul 2009 Results have been presented in an ARYx Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top